The National Trial Lawyers
  • Home
    • Meet Our Team
    • Contact Us
    • Mission & Goals
    • FAQ
  • Webinars
  • News
  • Membership Directory
    • Top 100 Map – Civil Plaintiff
    • Top 100 Map – Criminal Defense
    • Top 40 Under 40 Map – Civil Plaintiff
    • Top 40 Under 40 Map – Criminal Defense
  • Top 100
    • Civil Plaintiff Officers / Executive Committee
    • Criminal Defense Officers / Executive Committee
    • Benefits
    • About
    • Top 100 Presidents Message
    • Diplomat
    • Membership Renewal
    • Member Profile Updates
    • Top 100 Badge
  • Top 40
    • Civil Plaintiff Officers / Executive Committee
    • Criminal Defense Officers / Executive Committee
    • Top 40 Under 40 Trial Academy Bootcamp
    • Benefits
    • About
    • Top 40 Presidents Message
    • Membership Renewal
    • Member Profile Updates
    • Top 40 Badge
  • Specialty Assoc
    • About
    • Shop
    • Officers
    • Membership Renewal
    • Member Profile Updates
  • Nominate
    • Top 100
    • Top 40
    • Specialty Association
    • Trial Lawyer Hall of Fame
    • Trial Lawyer of the Year
    • Trial Team of the Year
    • America’s Most Influential Trial Lawyer
    • America’s Most Influential Law Firm
    • Lifetime Achievement Award
  • Shop
  • Magazine
    • A-List
  • Education and Networking Agenda
    • Trial Lawyers Summit
    • Top 40 Under 40 Trial Academy Boot Camp
    • Mass Torts Made Perfect
    • The Lanier Trial Academy Master Class 6.0
    • The Business Of Law
    • Webinars
  • Hall of Fame
    • Trial Lawyer Hall of Fame

Bladder Cancer Risks Don’t Deter FDA from Approving First Generic Actos

Posted on December 10, 2012 by webadmin

NewsInferno; August 20, 2012

In spite of serious concerns that Actos (pioglitazone) can cause bladder cancer and other serious side effects, the Food & Drug Administration (FDA) has approved the first generic version of the type 2 diabetes drug for sale in the U.S.  According to a statement from the agency, Mylan Pharmaceuticals, based in Morgantown, West Virginia, has been granted approval to market 15, 30, and 45  milligram pioglitazone tablets.

Actos is one of the top selling type 2 diabetes medications in the world.  According to the FDA, generic versions of Actos will offer affordable treatment options for patients who must manage this chronic and potentially serious condition.  However, critics of the FDA will surely raise concerns that widely available generic versions of Actos will put more patients at risk for its serious side effects, including bladder cancer.

Last June, the FDA issued a safety communication stating that use of Actos for more than one year may be associated with an increased risk of bladder cancer.  That same month, the French and German governments decided to suspend sales of Actos in those countries after a separate study commissioned by French regulators demonstrated an increased risk of bladder cancer associated with Actos in people who took it the longest and at the highest cumulative dose. Takeda Pharmaceuticals has officially recalled Actos from the market in France.

Since the FDA issued its warning last June, a number of new studies have confirmed the link between Actos and bladder cancer.  Most recently, research  published in the Journal of the National Cancer Institute found that patients taking Actos and other thiazolidinediones face as high as a 3-fold increased risk of developing bladder cancer, compared to patients who use sulfonylurea drugs, another common class of type 2 diabetes medications.   Last month, a study published in the Canadian Medical Association Journal (CMAJ) found a 22 percent increased risk of bladder cancer when taking Actos. In May, a Canadian study published in the British Medical Journal found that taking Actos for two years doubled the risk of bladder cancer.

Takeda Pharmaceuticals has been named in a number of U.S. lawsuits that accuse it of concealing knowledge of Actos’ bladder cancer risks and failing to adequately warn consumer and health care providers about its association with bladder cancer.  Most Actos bladder cancer lawsuits have been consolidated in a multidistrict litigation in U.S. District Court, Western District of Louisiana. As we’ve reported previously, some legal experts estimate that Takeda could face as many as 10,000 Actos bladder cancer lawsuits in the U.S.

Bladder cancer is not the only side effect associated with use of Actos.  The drug already bears a Black Box Warning, the FDA’s most urgent safety notice, stating that it may cause or worsen congestive heart failure in some patients.  Actos is not recommended for anyone who has symptomatic heart failure. Studies have also linked Actos to fractures, and an eye disorder called diabetic macular edema.

http://www.newsinferno.com/pharmaceuticals/bladder-cancer-risks-dont-deter-fda-from-approving-first-generic-actos/40288

 

Posted in Blog | Tagged Actos, FDA

Comments are closed.

Recent Posts

Salmon Purchasers Reach an $85 Million Price Fixing Settlement

Salmon Purchasers Reach an $85 Million Price Fixing Settlement

May 27th, 2022

According to Reuters, who had seen the proposed settlement after it was filed on 25 May, the settlement will r[Read More...]
Ford Agrees to Pay $19 Million to Settle False Fuel Economy and Payload Claims

Ford Agrees to Pay $19 Million to Settle False Fuel Economy and Payload Claims

May 27th, 2022

Ford Motor Company as agreed to a $19.2 million multistate settlement among 40 attorneys general that concluded an investigat[Read More...]
Total Settlement in Surfside Condo Collapse Tops $1 Billion

Total Settlement in Surfside Condo Collapse Tops $1 Billion

May 25th, 2022

The proposed settlement reached nearly a year after the catastrophic Surfside building collapse along the South Flo[Read More...]
UCLA Will Pay Nearly $700 Million in Abuse Lawsuits

UCLA Will Pay Nearly $700 Million in Abuse Lawsuits

May 25th, 2022

The University of California system announced Tuesday it will pay nearly $375 million to more than 300 women who said they we[Read More...]
Things to Consider When You Sue an Insurance Provider

Things to Consider When You Sue an Insurance Provider

May 24th, 2022

We are all too acquainted with insurance coverage in our everyday lives. According to Investopedia, everyone should have[Read More...]

Contact Us | Terms of Use | Privacy Policy

Attorney information and content provided on this website is provided for the benefit of members of The National Trial Lawyers and as a public service by Legal Associations Management, Inc. The website and all data are the property of Legal Associations Management, Inc. Data, including without limitation attorney information and content, on the site may not be mined, sold, or used commercially for any purpose without the explicit written consent of Legal Associations Management, Inc. This site may not be accessed by any automated program for extracting data for any use. By accessing and using the site you agree that you will not develop, support or use software, devices, scripts, robots, or any other means or processes (including crawlers, browser plug-ins and add-ons, or any other technology) to scrape data or otherwise copy profiles and other data. Unauthorized use or attempted unauthorized use of this system may subject you to both civil and criminal penalties.